Cargando…
The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic
BACKGROUND: Many in-person congresses have shifted to a virtual format owing to coronavirus disease 2019 (COVID-19). We assessed carbon emissions savings associated with virtual attendance at international medical congresses for a mid-sized pharmaceutical company, to identify which aspects are drivi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881751/ https://www.ncbi.nlm.nih.gov/pubmed/35218551 http://dx.doi.org/10.1007/s40290-022-00421-3 |
_version_ | 1784659542860103680 |
---|---|
author | Gattrell, William T. Barraux, Aurélie Comley, Sam Whaley, Michael Lander, Nicholas |
author_facet | Gattrell, William T. Barraux, Aurélie Comley, Sam Whaley, Michael Lander, Nicholas |
author_sort | Gattrell, William T. |
collection | PubMed |
description | BACKGROUND: Many in-person congresses have shifted to a virtual format owing to coronavirus disease 2019 (COVID-19). We assessed carbon emissions savings associated with virtual attendance at international medical congresses for a mid-sized pharmaceutical company, to identify which aspects are driving the carbon cost. METHODS: We assessed carbon emissions that were the responsibility of company attendees (including their guests) for the most attended congresses by employees (American Society of Clinical Oncology [ASCO], European Neuroendocrine Tumor Society [ENETS], European Society for Medical Oncology [ESMO], World Congress for NeuroRehabilitation [WCNR]). For in-person estimates, we considered travel, accommodation and congress attendance; for online estimates, we considered office and internet-related energy use. Emissions were defined using recognised data sources. RESULTS: For 1723 anticipated in-person attendees, calculated total carbon emissions were 3,262,574 kgCO(2e) (mean per in-person company attendee, 1894 kgCO(2e): ASCO, 4172; ESMO, 1479; WCNR, 1153; ENETS, 1009). For context, the average UK resident’s annual carbon footprint is 5600 kgCO(2e). Travel accounted for 91–96% of total emissions, mainly through long distance and business-class air travel. Calculated total carbon emissions associated with 1839 virtual attendees were 19,095 kgCO(2e) (mean per virtual company attendee, 10.4 kgCO(2e); equivalent to approximately 0.3–1.1% of in-person attendance emissions across all four congresses assessed). CONCLUSION: Carbon emissions associated with virtual attendance were two orders of magnitude lower than for in-person attendance, and therefore the benefits of in-person attendance at medical congresses must be balanced against the carbon cost. Due diligence around who should attend and how they should travel to face-to-face meetings, and consideration of hybrid and domestic satellite options could be part of a balanced solution to reducing carbon emissions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40290-022-00421-3. |
format | Online Article Text |
id | pubmed-8881751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88817512022-02-28 The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic Gattrell, William T. Barraux, Aurélie Comley, Sam Whaley, Michael Lander, Nicholas Pharmaceut Med Original Research Article BACKGROUND: Many in-person congresses have shifted to a virtual format owing to coronavirus disease 2019 (COVID-19). We assessed carbon emissions savings associated with virtual attendance at international medical congresses for a mid-sized pharmaceutical company, to identify which aspects are driving the carbon cost. METHODS: We assessed carbon emissions that were the responsibility of company attendees (including their guests) for the most attended congresses by employees (American Society of Clinical Oncology [ASCO], European Neuroendocrine Tumor Society [ENETS], European Society for Medical Oncology [ESMO], World Congress for NeuroRehabilitation [WCNR]). For in-person estimates, we considered travel, accommodation and congress attendance; for online estimates, we considered office and internet-related energy use. Emissions were defined using recognised data sources. RESULTS: For 1723 anticipated in-person attendees, calculated total carbon emissions were 3,262,574 kgCO(2e) (mean per in-person company attendee, 1894 kgCO(2e): ASCO, 4172; ESMO, 1479; WCNR, 1153; ENETS, 1009). For context, the average UK resident’s annual carbon footprint is 5600 kgCO(2e). Travel accounted for 91–96% of total emissions, mainly through long distance and business-class air travel. Calculated total carbon emissions associated with 1839 virtual attendees were 19,095 kgCO(2e) (mean per virtual company attendee, 10.4 kgCO(2e); equivalent to approximately 0.3–1.1% of in-person attendance emissions across all four congresses assessed). CONCLUSION: Carbon emissions associated with virtual attendance were two orders of magnitude lower than for in-person attendance, and therefore the benefits of in-person attendance at medical congresses must be balanced against the carbon cost. Due diligence around who should attend and how they should travel to face-to-face meetings, and consideration of hybrid and domestic satellite options could be part of a balanced solution to reducing carbon emissions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40290-022-00421-3. Springer International Publishing 2022-02-26 2022 /pmc/articles/PMC8881751/ /pubmed/35218551 http://dx.doi.org/10.1007/s40290-022-00421-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Gattrell, William T. Barraux, Aurélie Comley, Sam Whaley, Michael Lander, Nicholas The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
title | The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
title_full | The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
title_fullStr | The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
title_full_unstemmed | The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
title_short | The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic |
title_sort | carbon costs of in-person versus virtual medical conferences for the pharmaceutical industry: lessons from the coronavirus pandemic |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881751/ https://www.ncbi.nlm.nih.gov/pubmed/35218551 http://dx.doi.org/10.1007/s40290-022-00421-3 |
work_keys_str_mv | AT gattrellwilliamt thecarboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT barrauxaurelie thecarboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT comleysam thecarboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT whaleymichael thecarboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT landernicholas thecarboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT gattrellwilliamt carboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT barrauxaurelie carboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT comleysam carboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT whaleymichael carboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic AT landernicholas carboncostsofinpersonversusvirtualmedicalconferencesforthepharmaceuticalindustrylessonsfromthecoronaviruspandemic |